Reproductive and lifestyle factors and circulating sRANKL and OPG concentrations in women: Results from the EPIC cohort
Sarink, Danja; Yang, Jiaxi; Johnson, Theron; Chang-Claude, Jenny; Overvad, Kim; Olsen, Anja; Tjonneland, Anne; Fournier, Agnes; Kvaskoff, Marina; Romana Mancini, Francesca; Boeing, Heiner; Trichopoulou, Antonia; Karakatsani, Anna; Valanou, Elissavet; Agnoli, Claudia; Sacerdote, Carlotta; Masala, Giovanna; Mattiello, Amalia; Tunino, Rosario; van Gils, Carla H; Skeie, Guri; Gram, Inger T; Weiderpass, Elisabete; Lujan-Barroso, Leila; Petrova, Dafina; Santiuste, Carmen; Quirós, J Ramón; Barricarte, Aurelio; Amiano, Pilar; Travis, Ruth C; Gunter, Marc J; Dossus, Laure; Christakoudi, Sofia; Kaaks, Rudolf; Fortner, Renée T
(2019) Cancer Epidemiology Biomarkers & Prevention, volume 28, issue 10, pp. 1746 - 1754
(Article)
Abstract
BACKGROUND: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in
... read more
pre- and postmenopausal women. METHODS: This study includes 2,016 controls [ n = 1,552 (76%) postmenopausal, n = 757 (38%) using postmenopausal hormone therapy (PMH)] from a breast cancer case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an ELISA and serum OPG using an electrochemiluminescent assay. Generalized linear models were used to evaluate associations between these analytes and reproductive and lifestyle factors. RESULTS: Older age at blood collection was associated with lower sRANKL concentrations in postmenopausal women ( P trend ≤ 0.03) and higher OPG concentrations in all women ( P trend ≤ 0.01). Longer duration of oral contraceptive use among premenopausal women and postmenopausal PMH users was associated with higher OPG ( P trend ≤ 0.04). In postmenopausal non-PMH users, sRANKL concentrations were lower with longer duration of oral contraceptive use and current (vs. never) smoking ( P ≤ 0.01). sRANKL concentrations were higher among women with higher BMI ( P trend ≤ 0.01). The evaluated factors accounted for 12% of the variation in sRANKL concentrations and 21% of the variation in OPG concentrations. CONCLUSIONS: Circulating sRANKL and OPG concentrations are minimally impacted by hormone-related factors in pre- and postmenopausal women. IMPACT: This study suggests circulating concentrations of sRANKL and OPG are unlikely to be strongly modified by hormone-related reproductive and lifestyle factors.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Epidemiology, Oncology
ISSN: 1055-9965
Publisher: American Association for Cancer Research Inc.
Note: Funding Information: This project was funded by research grant #111454 from the Deutsche Kresbshilfe. R.T. Fortner was supported by aMarie Curie International Incoming Fellowship of the European Commission's Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM; France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy andNational Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada; PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/ M012190/1 to EPIC-Oxford; United Kingdom). Publisher Copyright: © 2019 American Association for Cancer Research.
(Peer reviewed)